News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Altravax, Inc. Awarded $1.2 Million to Advance Dengue Vaccine and Hepatitis Therapeutic


1/8/2013 9:17:13 AM

FARGO, N.D. & SUNNYVALE, Calif.--(BUSINESS WIRE)--Altravax, Inc. announced today that it has been awarded two Advanced Technology Small Business Innovation Research grants from the NIH’s National Institute of Allergy and Infectious Diseases for research on vaccines to prevent infection by dengue virus and to treat chronic hepatitis B. Each of these viruses is a global problem and the focus of Altravax’s two lead commercial programs.

Read at BioSpace.com

comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES